Tomasz Beer, MD
Medical Oncology · Portland, ORNPI 1669487179
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $82,933 of the $102,159 with a category attached, or 81.2%. 14 manufacturers reported payments, led by Astrazeneca UK Limited at 26.3% of the total. Reporting peaked in 2019 at $34,543 and has fallen 86.1% since, to $4,800 in 2025. Among medical oncology clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 77 payments — averaging $1326.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astrazeneca UK Limited$27K
- Bayer$17K
- Pfizer$14K
- Sanofi$12K
- Astellas Pharma Global Development$7K
- E.r. Squibb & Sons, L.L.C.$5K
- plus $19K from 8 others
Across 76 payments — averaging $9414.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bayer$300K
- Merck$217K
- Corcept Therapeutics$130K
- Astellas Pharma Global Development$50K
- Boehringer Ingelheim$15K
- Pfizer$4K
- plus $45 from 1 others
What the payments were for
- Consulting fees$82,93381%
- Speaking & faculty fees$14,45514%
- Travel & lodging$2,8863%
- Food & beverage$1,8722%
- Education$130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astrazeneca UK Limited | 17 | $26,878 |
| Bayer | 19 | $17,497 |
| Pfizer | 11 | $14,145 |
| Sanofi | 7 | $12,376 |
| Astellas Pharma Global Development | 6 | $7,217 |
| E.r. Squibb & Sons, L.L.C. | 2 | $5,288 |
| Advanced Accelerator Applications | 3 | $4,903 |
| Siemens Medical Solutions USA, Inc. | 1 | $3,150 |
| Progenics Pharmaceuticals, Inc. | 4 | $2,983 |
| GSK | 2 | $2,250 |
| Janssen Scientific Affairs, LLC | 1 | $2,020 |
| Clovis Oncology, Inc. | 2 | $2,002 |
| Myovant Sciences Inc. | 1 | $775 |
| AbbVie | 1 | $675 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$102,159 in reported general payments places this provider in the 95th percentile of 92 medical oncology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 78 | $1,050,826 |
| NubeqaDarolutamide | 44 | $544,852 |
| OrgovyxRelugolix | 24 | $62,119 |
| Abiraterone Acetate | 74 | $58,736 |
| Bicalutamide | 23 | $1,964 |
| Prednisone | 22 | $202 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerNubeqa | $17,497 | $544,85244 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $2,020 | $58,73674 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 92 medical oncology providers in Oregon.
Other medical oncology in Portland
- David PagePortland$238K
- Rachel SanbornPortland$233K
- Matthew TaylorPortland$231K
- Alison ConlinPortland$85K
- Shivaani KummarPortland$66K
- Stacy LewisPortland$57K
- Hagen KenneckePortland$53K
- Adel KardoshPortland$51K
- Brendan CurtiPortland$49K
- Rom LeidnerPortland$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.